These payloads block another protein that can protect cancer cells from dying. Antibody delivery is being studied to direct that effect toward selected blood cancers.
S227928 links the MCL-1 inhibitor S64315, also called MIK665, to a CD74-directed antibody. The primary ASH abstract reported intracellular payload release and target engagement in leukemia models. Single-agent activity was modest in the reported models, while combining the conjugate with the separate BCL-2 inhibitor venetoclax increased activity. This is an MCL-1 payload plus a separate drug, not a dual-payload construct. Preclinical results and a registered early trial do not establish clinical benefit or removal of the safety concerns associated with MCL-1 inhibition.
In plain words · MCL1 (Induced myeloid leukaemia cell differentiation protein Mcl-1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma.
Showing the target this term concerns: MCL1.
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/